Compound 15c, a Novel Dual Inhibitor of EGFR(L858R/T790M) and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers

In the past decades, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) had been proved as an effective treatment strategy for the patients with EGFR-mutated non-small-cell lung cancer (NSCLC). However, the tolerance for the EGFR-TKI always occurred after continuous administrati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Gaozhi, Bao, Yuyan, Weng, Qiaoyou, Zhao, Yingxin, Lu, Xiaoyao, Fu, Lili, Chen, Lingfeng, Liu, Zhiguo, Zhang, Xiaomin, Liang, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965315/
https://www.ncbi.nlm.nih.gov/pubmed/31998131
http://dx.doi.org/10.3389/fphar.2019.01533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965315/
https://www.ncbi.nlm.nih.gov/pubmed/31998131
http://dx.doi.org/10.3389/fphar.2019.01533

Ejemplares similares